Essa Pharma - Developing the Next Generation of Treatments ...
ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, masofaniten (formerly EPI-7386), represents a new approach to disrupting the androgen receptor signaling pathway, the primary driver of prostate cancer growth.
ESSA Pharma Inc. (EPIX) Stock Price, News, Quote & History
Find the latest ESSA Pharma Inc. (EPIX) stock quote, history, news and other vital information to help you with your stock trading and investing.
ESSA Stops Phase 2 Study Of Masofaniten Combo In Metastatic …
Nov 1, 2024 · (RTTNews) - ESSA Pharma Inc. (EPIX) announced that it has made the decision to terminate the Phase 2 clinical trial evaluating in a 2:1 randomization masofaniten combined with enzalutamide versus ...
ESSA Pharma Provides Corporate Update and Reports Financial …
Dec 12, 2023 · ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a...
ESSA Pharma Announces First Patient Dosed in a Phase 1/2 …
Jan 19, 2022 · HOUSTON and VANCOUVER, BC, Jan. 19, 2022 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel...
ESSA Pharma Inc. (EPIX) Latest Stock News & Headlines - Yahoo …
Get the latest ESSA Pharma Inc. (EPIX) stock news and headlines to help you in your trading and investing decisions.
ESSA Pharma Provides Corporate Update and Reports Financial …
Dec 12, 2023 · SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company,...
ESSA Pharma Presents Preclinical Data for its First Generation …
Oct 26, 2022 · The preclinical data demonstrate that EPI-8207, an ANITAC, shows robust potency degrading AR, including AR splice variants and clinically relevant AR mutants that can potentially drive disease...
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) …
Oct 21, 2023 · SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Oct. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical …
ESSA Pharma Inc. (EPIX) Stock Price, Quote & News - Stock …
5 days ago · Get a real-time ESSA Pharma Inc. (EPIX) stock price quote with breaking news, financials, statistics, charts and more.